Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer (source: Medical News Today)

Mar

Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer (source: Medical News Today)

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck KGaA/Oncothyreon's Stimuvax vaccine earns Decision Resources' proprietary clinical gold standard status in 2013 and 2018 f... (source: Medical News Today) - RSS news feeds and Widgets on Feedzilla.com

Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer (source: Medical News Today)

Post new comment